Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. YCBD
YCBD logo

YCBD Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy cbdMD Inc (YCBD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
0.700
1 Day change
4.77%
52 Week Range
3.360
Analysis Updated At
2026/03/06
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Based on the data provided, cbdMD Inc (YCBD) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock exhibits weak financial performance, no significant positive catalysts, bearish technical indicators, and lacks any recent influential trading activity or news to suggest a turnaround.

Technical Analysis

The technical indicators for YCBD are bearish. The MACD histogram is negative and contracting, the RSI is neutral at 42.478, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 0.714 and resistance at 0.87. This suggests a lack of upward momentum.

Positive Catalysts

  • NULL identified. There is no recent news, influential trading activity, or positive financial trends to act as a catalyst for the stock.

Neutral/Negative Catalysts

  • The company reported a significant decline in financial performance in Q1 2026, including a 67.06% drop in net income, a 97.69% drop in EPS, and a 9.48% decline in gross margin. Additionally, the stock's technical indicators and trading trends are bearish or neutral, with no signs of recovery.

Financial Performance

In Q1 2026, cbdMD Inc reported a revenue decline of -1.89% YoY to $5,016,904. Net income dropped significantly by -67.06% YoY to -$324,602, and EPS fell by -97.69% YoY to -0.04. Gross margin also declined to 54.93%, down -9.48% YoY. These metrics indicate poor financial health and growth prospects.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data on analyst ratings or price target changes is available for YCBD.

Wall Street analysts forecast YCBD stock price to rise
1 Analyst Rating
Wall Street analysts forecast YCBD stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.670
sliders
Low
2
Averages
2
High
2
Current: 0.670
sliders
Low
2
Averages
2
High
2
Maxim
Buy
downgrade
$3 -> $2
AI Analysis
2025-08-20
Reason
Maxim
Price Target
$3 -> $2
AI Analysis
2025-08-20
downgrade
Buy
Reason
Maxim lowered the firm's price target on cbdMD to $2 from $3 and keeps a Buy rating on the shares. The firm cites the company's Q3 loss coming in wider than expected amid softness in demand and regulatory uncertainties, the analyst tells investors in a research note. Maxim adds that while the company has partnered with industry advocacy groups to engage legislators and prioritize compliance with product quality and labeling requirements, it expects regulatory headwinds to persist, limiting growth through 2026.
Maxim
Buy
downgrade
$16 -> $3
2025-05-22
Reason
Maxim
Price Target
$16 -> $3
2025-05-22
downgrade
Buy
Reason

People Also Watch